Background stories of how others approached and experienced their European Horizon funding trajectory.
If you’ve never heard of Limecraft, you’re clearly not working in the media sector. Their SaaS platform provides integrated workflows for media management, scripted and unscripted TV, and subtitling and localisation. It is used by leading broadcasting companies – such as BBC, VRT, NPO… – and production firms of which De Mensen or Hotel Hungaria might ring a bell (at least if you are Belgian).
NCP Flanders went to Ghent to interview Maarten Verwaest, CEO and cofounder, about how he sees Horizon 2020. Limecraft is a partner in the MeMAD project, which is a collaborative RIA project submitted to an ICT call topic.
Read the full article for details
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.